Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Federal Grant Posted Active

Program Number (CFDA) PAR-25-226

Agency National Institutes of Health

Program Type Posted

Total Funding $0

Status Active

Opportunity #: PAR-25-226. Agency: National Institutes of Health. Status: Posted. Closes: 11/19/2026. Posted: 11/22/2024.

🎯 Get GovCon Intel Free →

Get Federal ContractingIntelligence — Free